Insights into PrBYOOVIZTM
Exploring patient narratives1,2
Meet Barbara
A 91-year-old female with neovascular age-related macular degeneration (nAMD) who had not been treated before BYOOVIZ.
- Presenting visual acuity: 20/200
- Last follow-up visual acuity: 20/60
Based on real patients: fictitious images and personal narratives are shown. May not be representative of the general population.
Meet Doug
An 81-year-old male with macular edema secondary to retinal vein occlusion (RVO) who switched to BYOOVIZ after initial treatment with PrLUCENTIS®.
- Presenting visual acuity: 20/80
- Last follow-up visual acuity: 20/40
Based on real patients: fictitious images and personal narratives are shown. May not be representative of the general population.
Meet Laura
A 94-year-old female with nAMD who switched to BYOOVIZ after treatment with LUCENTIS.
- Presenting visual acuity: 20/100
- Last follow-up visual acuity: 20/40
Based on real patients: fictitious images and personal narratives are shown. May not be representative of the general population.
